Adiponectin may be related to skin remodelling in patients with systemic sclerosis

Authors: M. Tomčík 1;  H. Hulejová 1;  M. Filková 1;  M. Braun 1;  R. Bečvář 1;  M. Haluzík 2;  L. Šenolt 1
Authors‘ workplace: Revmatologický ústav, Praha, 2III. Interní klinika – klinika endokrinologie a metabolizmu 1. LF a VFN, Praha 1
Published in: Čes. Revmatol., 16, 2008, No. 4, p. 148-152.
Category: Original Papers


Adiponectin and resistin represent well known adipokines that have been initially described as regulators of metabolic homeostasis, and subsequently proposed as modulators of inflammatory properties, particularly in rheumatic and vascular diseases. Systemic sclerosis (SSc) is a systemic autoimmune disorder characterized particularly by fibrotic thickening of skin, vessel walls and visceral organs.

Patients and methods:
Sixteen patients with SSc were retrospectively evaluated in this study. The modified Rodnan skin score was determined in 10 patients. The control group included 16 healthy individuals. Serum levels of adiponectin and resistin were determined by commercial ELISA kits in both groups. Urine samples were analyzed for pyridinoline (U-PD) and deoxypyridinoline (U-DPD) by high-performance liquid chromatography.

Adiponectin serum levels were significantly decreased in patients with SSc compared to healthy controls (p<0.02). On the other hand, resistin serum levels were similar in both groups (p=0.90). The serum levels of adiponectin, but not resistin, positively correlated with urine markers of collagen degradation U-PD (p<0.01) and U-DPD (p<0.05) and negatively correlated with the skin score (p<0.01). Conclusion: The decreased levels of adiponectin, its relationship to decreased collagen turnover and increased fibrotic remodelling of skin, might be important in the course of systemic sclerosis.

Key words:
systemic sclerosis, fibrosis, adiponectin, resistin, skin score


1. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006; 45 Suppl 3:iii26–7.

2. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 70: 26746–9.

3. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–12.

4. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525–46.

5. Shin HJ, Park S, Yoon SJ, et al. Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol 2008 Mar; 125: 79–84.

6. Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53: 123–9.

7. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–7.

8. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, Kulkarni KR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 2008; 31: 989–94.

9. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007; 98: 1120–7.

10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772–83.

11. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3: 716–24.

12. Šenolt L, Housa D, Vernerová Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458–63.

13. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789–95.

14. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol 2006; 176: 4468–78.

15. Šenolt L, Pavelka K, Housa D, Haluzík M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006; 35: 247–52.

16. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655–69.

17. Renigunta A, Hild C, Rose F, et al. Human RELMbeta is a mitogenic factor in lung cells and induced in hypoxia. FEBS Lett 2006; 580: 900–3.

18. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.

19. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979 Feb; 22(2): 130–40.

20. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 Nov; 20(11): 1892–6.

21. Bečvář R, Štork J, Pešáková V, et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404–12.

22. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125: 1796–1807.

23. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91–100.

24. Laplante P, Raymond MA, Gagnon G, et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005 May 1; 174(9): 5740–9.

25. Tomasek J J, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002 May; 3(5):349–63

26. Khurma V, Meyer C, Park GS, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 2008; 59: 591–7.

Dermatology & STDs Paediatric rheumatology Rheumatology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account